Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
Tatsuo Sugawara, Simon J. Baumgart, Ekaterina Nevedomskaya, et al.
International Journal of Cancer (2019) Vol. 145, Iss. 5, pp. 1382-1394
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
Stefanie Hammer, Urs B. Hagemann, Sabine Zitzmann-Kolbe, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 8, pp. 1985-1996
Open Access | Times Cited: 105
Resistance to second-generation androgen receptor antagonists in prostate cancer
Keith T. Schmidt, Alwin D. R. Huitema, Cindy H. Chau, et al.
Nature Reviews Urology (2021) Vol. 18, Iss. 4, pp. 209-226
Closed Access | Times Cited: 86
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment
Fabio Raith, Daniel H. O’Donovan, Clara Lemos, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2289-2289
Open Access | Times Cited: 23
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis
Tatsuo Sugawara, Ekaterina Nevedomskaya, Simon Heller, et al.
Molecular Oncology (2024) Vol. 18, Iss. 3, pp. 726-742
Open Access | Times Cited: 10
Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
Pietro Delre, Fabiana Caporuscio, Michele Saviano, et al.
Frontiers in Chemistry (2020) Vol. 8
Open Access | Times Cited: 51
Androgen receptor mutations for precision medicine in prostate cancer
Masaki Shiota, Shusuke Akamatsu, Shigehiro Tsukahara, et al.
Endocrine Related Cancer (2022) Vol. 29, Iss. 10, pp. R143-R155
Open Access | Times Cited: 36
Updates on Drug Designing Approach Through Computational Strategies: a Review
Iqbal Azad, Tahmeena Khan, Naseem Ahmad, et al.
Future Science OA (2023) Vol. 9, Iss. 5
Open Access | Times Cited: 20
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023
Thomas P. Burris, Ian Mitchelle S. de Vera, Isabelle Côté, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 6, pp. 1233-1318
Open Access | Times Cited: 19
Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
Eva Estébanez‐Perpiñá, Charlotte L. Bevan, Iain J. McEwan
Cancers (2021) Vol. 13, Iss. 3, pp. 509-509
Open Access | Times Cited: 38
New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact
Lorenzo Gasperoni, Emilio Francesco Giunta, Daniela Montanari, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 6, pp. 491-502
Open Access | Times Cited: 5
Emerging therapeutic agents for genitourinary cancers
Kevin Zarrabi, Azzam Paroya, Shenhong Wu
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 42
Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
Daisuke Obinata, Mitchell G. Lawrence, Ken‐ichi Takayama, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 34
Darolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation
Simon J. Baumgart, Ekaterina Nevedomskaya, Ralf Lesche, et al.
Molecular Oncology (2020) Vol. 14, Iss. 9, pp. 2022-2039
Open Access | Times Cited: 32
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer
Nicholas Mitsiades, Salma Kaochar
Endocrine Related Cancer (2021) Vol. 28, Iss. 8, pp. T19-T38
Open Access | Times Cited: 29
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer
Yali He, Dong‐Jin Hwang, Suriyan Ponnusamy, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 11045-11062
Open Access | Times Cited: 28
Discovery of novel spirocyclic derivates as potent androgen receptor antagonists
Wenqiang Zhang, Xiaoyu Zhou, Hao‐Jie Zhu, et al.
Bioorganic & Medicinal Chemistry (2025), pp. 118082-118082
Closed Access
Engineered cell nanovesicle antagonists for androgen deprivation therapy of melanoma
Yu Zhao, Yichuan Ma, Qingqing Leng, et al.
Journal of Colloid and Interface Science (2025), pp. 137468-137468
Closed Access
Discovery of Novel Bifunctional Agents as Potent Androgen Receptor Antagonists and Degraders for the Treatment of Enzalutamide-Resistant Prostate Cancer
Wenqiang Zhang, Hao‐Jie Zhu, Zhuolin Chen, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity
Wen‐Bing Jin, Leyi Xiao, Mingeum Jeong, et al.
Cell (2025)
Closed Access
Darolutamide: First Approval
Anthony Markham, Sean T. Duggan
Drugs (2019) Vol. 79, Iss. 16, pp. 1813-1818
Closed Access | Times Cited: 31
Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer
Miriam Kokal, Kimia Mirzakhani, Thanakorn Pungsrinont, et al.
Cancers (2020) Vol. 12, Iss. 7, pp. 1833-1833
Open Access | Times Cited: 30
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer
Yali He, Dong‐Jin Hwang, Suriyan Ponnusamy, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12642-12665
Open Access | Times Cited: 28
Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells
Wenting Pan, Zhouwei Zhang, Hannah Kimball, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 7, pp. 2087-2099
Open Access | Times Cited: 26
An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)
S. Vishakha, N. Navneesh, Balak Das Kurmi, et al.
Anti-Cancer Agents in Medicinal Chemistry (2024) Vol. 24, Iss. 8, pp. 590-626
Closed Access | Times Cited: 3
UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer
Soohyun Lee, Hwa‐Ryeon Kim, Yaejin Woo, et al.
Advanced Science (2024) Vol. 11, Iss. 33
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top